McKesson's Board Clears Itself of Fault on Opioid Oversight
- Executives ‘placed great emphasis on compliance,’ panel says
- Almost 45,000 people died in year through July 2017, CDC says
This article is for subscribers only.
A year after McKesson Corp. announced a $150 million settlement with the U.S. government over allegations it failed to properly oversee shipments of painkillers, a board committee cleared directors and senior executives of wrongdoing.
The drug distributor’s executives “placed great emphasis on compliance, encouraged ethical conduct” and improved the company’s opioid-monitoring processes, a panel of three independent directors said in an April 20 report.